BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arena R, Cecinato P, Lisotti A, Buonfiglioli F, Calvanese C, Grande G, Montagnani M, Azzaroli F, Mazzella G. Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature. World J Hepatol 2015; 7(12): 1718-1722 [PMID: 26140092 DOI: 10.4254/wjh.v7.i12.1718] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39-50. [PMID: 27186144 DOI: 10.2147/hmer.s74612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
2 Ichimata S, Kobayashi M, Honda K, Shibata S, Matsumoto A, Kanno H. Acquired amegakaryocytic thrombocytopenia previously diagnosed as idiopathic thrombocytopenic purpura in a patient with hepatitis C virus infection. World J Gastroenterol 2017; 23(35): 6540-6545 [PMID: 29085203 DOI: 10.3748/wjg.v23.i35.6540] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Zhang Z, Zhang Y, Song S, Yin L, Sun D, Gu J. Recent advances in the bioanalytical methods of polyethylene glycols and PEGylated pharmaceuticals. J Sep Sci 2020;43:1978-97. [DOI: 10.1002/jssc.201901340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]